April 8, 2013

BrainStorm Partners with Dana-Farber for NurOwn™ Production in Phase II ALS Clinical Trial

NEW YORK & PETACH TIKVAH, Israel – April 8, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dana-Farber Cancer Institute (“Dana-Farber”) has entered into an agreement to provide cGMP-compliant clean room facilities for production of BrainStorm’s NurOwn™ stem cell candidate during its upcoming Phase II ALS trial in the USA.  The Company’s Phase II trial, to be launched in the second half of 2013 pending FDA approval, will be conducted at Massachusetts General Hospital (“MGH”), the University of Massachusetts (“UMass”) Hospital and the Mayo Clinic. The Connell and O'Reilly Cell Manipulation Core Facility at Dana-Farber will produce NurOwn for the MGH and UMass Hospital clinical sites.

Read more: April 8, 2013

March 25, 2013

BRAINSTORM PROVIDES RECENT CORPORATE AND CLINICAL DEVELOPMENT UPDATE

• ·         NurOwn™ Clinical Trial Suggests Efficacy In Patients with ALS
• ·         Mayo Clinic Joins MGH and UMass to Conduct Phase II Clinical Trial of BrainStorm’s NurOwn™ in ALS

New York, NY and Petach Tikvah, Israel, March 25, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided an update on the company’s development of its NurOwn™ technology in the treatment of patients with ALS, also known as Lou Gehrig’s disease. 

Read more: March 25, 2013

March 21, 2013

RESULTS OF NUROWN™ CLINICAL TRIAL SUGGEST EFFICACY IN ALS PATIENTS

Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function

New York, NY and Petach Tikvah, Israel – March 21, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the final results from a clinical study evaluating the company’s NurOwn™ technology in 12 ALS patients.  NurOwn is a proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells.  The data were presented yesterday, Wednesday, March 20, 2013 during the 65^th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, California.

Read more: March 21, 2013

March 18, 2013

Phase II ALS Clinical Trial with BrainStorm Cell Therapeutics’ NurOwn™ to be Expanded to a Third Premiere U.S. Clinical Site

NEW YORK & PETACH TIKVAH, Israel – March 18, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Mayo Clinic in Rochester, Minnesota has entered into a Memorandum of Understanding with the intent to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s Disease.  Mayo Clinic is the third premiere U.S. clinical site to sign a memorandum of understanding with the Company, following the University of Massachusetts, and Massachusetts General Hospital (MGH).

Read more: March 18, 2013

March 13, 2013

BrainStorm Cell Therapeutics Presents Breakthrough Phase I/II ALS Clinical Data at the American Academy of Neurology Annual Meeting

• American Academy of Neurology's Annual Meeting Being Held March 16-23 at the San Diego Convention Center
• BrainStorm Presentation:  Emerging Science Session on Wednesday, March 20, 2013

NEW YORK & PETACH TIKVAH, Israel – March 13, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting the initial results of its Phase I/II ALS trial at the 65^th  Annual Meeting of the American Academy of Neurology (AAN) in San Diego, California, from March 16-23. BrainStorm's groundbreaking clinical trial data were selected for one of only twelve oral presentations in the Emerging Science Session on Wednesday March 20^th.

Read more: March 13, 2013

March 8, 2013

BrainStorm Cell Therapeutics Presents at the 11^th International Conference On Alzheimer's and Parkinson’s Disease  

NEW YORK & PETACH TIKVAH, Israel – March 8, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2013) this week in Florence, Italy (http://www2.kenes.com/adpd/Pages/Home.aspx).

Read more: March 8, 2013

February 27, 2013

Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations

NEW YORK & PETACH TIKVAH, Israel—February 27, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the company was recently featured on national and local news, as well as Fox News.

Read more: February 27, 2013

February 13, 2013

BrainStorm to Present at the 8^th Annual New York Stem Cell Summit

NEW YORK & PETACH TIKVAH, Israel—February 13, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it will be presenting at the 8^th Annual New York Stem Cell Summit on Tuesday, February 19^th at 2:00 pm EST. The company’s Chief Medical Advisor, Prof. Eldad Melamed, MD, will discuss the latest scientific and clinical developments of NurOwn™, BrainStorm’s stem cell therapy candidate for ALS, including its recent acceleration to a Phase IIa dose-escalating trial by the Israeli Ministry of Health.

Read more: February 13, 2013